| Name | Title | Contact Details |
|---|
HONOUR is a global leader in chemistry-driven solutions, focusing on the pharmaceutical, electronics, and performance materials industries. The company emphasizes innovation and agility, supported by a strong scientific workforce. HONOUR specializes in Custom Synthesis and Contract Development and Manufacturing Organization (CDMO) services, offering a range of customizable chemicals and ingredients, including coupling reagents, excipients, and polymer monomers. The Research & Development team at HONOUR combines advanced chemistry and technology to create practical solutions tailored to the unique needs of its partners. The company values trust and integrity in its relationships, aiming to foster sustainable progress in collaboration with its clients. HONOUR serves a diverse clientele, including pharmaceutical companies and electronics manufacturers, providing them with expert R&D capabilities and customized chemical solutions.
DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.
Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.
Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.